Corey Cutler

TL;DR: The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence, and focuses attention on the causes of organ-specific abnormalities to chronic GVHD.

TL;DR: In this article, the authors proposed a new clinical scoring system (0-3) that describes the extent and severity of chronic graft-versus-host disease for each organ or site at any given time, taking functional impact into account.

TL;DR: Daily low-dose interleukin-2 was safely administered in patients with active chronic GVHD that was refractory to glucocorticoid therapy and was associated with preferential, sustained Treg cell expansion in vivo and amelioration of the manifestations of chronic GvHD in a substantial proportion of patients.

TL;DR: Compared with nonallogeneic SCT therapies, allogeneicSCT has significant RFS and overall survival benefit for intermediate- and poor-risk AML but not for good- risk AML in first complete remission.

TL;DR: A phase 3, multicenter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donors did not detect significant survival differences, and exploratory analyses of secondary end points indicated that peripheral- Blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduceThe risk of chronic GVHD.